A biosimilar version could shift that equation
On the cusp of autumn 2025, a European regulatory committee moved to widen the circle of care for millions living with chronic inflammatory disease, recommending approval of Gobivaz — Alvotech's biosimilar of golimumab — across the EU and EEA. The decision reflects a broader human effort to make complex, transformative medicines more accessible by cultivating competition in markets long shaped by high costs and limited supply. Though a final European Commission ruling remains, the recommendation signals that rigorous science and commercial partnership can together lower the barriers between patients and the therapies they need.
- Chronic inflammatory diseases like rheumatoid arthritis and ulcerative colitis affect tens of millions, yet the biologics that treat them remain financially out of reach for many patients worldwide.
- Alvotech's Gobivaz cleared a demanding scientific threshold — two clinical studies demonstrating pharmacokinetic and efficacy parity with the original Simponi — before earning the committee's positive opinion.
- The recommendation covers all 27 EU member states plus Norway, Iceland, and Liechtenstein, placing a potential market of 450 million people within reach of a more affordable TNF-alpha inhibitor.
- The European Commission has yet to issue formal marketing authorization, meaning the drug is approved in spirit but not yet in law — a procedural step that typically follows the committee's lead.
- For Alvotech, the win validates an eight-candidate pipeline and a global commercial network; for partner Advanz Pharma, it advances an ambition to become a leading biosimilars force in Europe.
On September 22, Europe's top medicines committee issued a positive recommendation for Gobivaz, a biosimilar version of golimumab developed by Icelandic biotech Alvotech. The drug targets the same conditions as its reference product Simponi — rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and juvenile idiopathic arthritis — and would be available in two pre-filled formulations suitable for home use via autoinjector.
Biosimilars are not simple copies. Because biologic medicines are structurally complex, companies must build their own manufacturing processes from the ground up and then prove through clinical trials that their version behaves essentially the same as the original. Alvotech met that bar through a 2023 pharmacokinetic study in healthy volunteers and a 2024 confirmatory efficacy trial in rheumatoid arthritis patients, both of which showed comparable performance to Simponi.
Golimumab works by blocking TNF-alpha, a protein central to the inflammatory processes that damage joints and tissue. For the roughly one percent of the global population living with rheumatoid arthritis alone, TNF inhibitors have been life-changing — but their cost has long limited access. A biosimilar entering the market adds supply, introduces price competition, and potentially extends treatment to patients who previously went without.
Advanz Pharma, a London-based specialty pharmaceutical firm, holds exclusive commercialization rights for Gobivaz across Europe, the UK, Switzerland, Canada, Australia, and New Zealand. Together, the two companies are positioned to move quickly once the European Commission issues its formal marketing authorization — a decision that customarily follows the committee's recommendation.
For Alvotech, the positive opinion is a meaningful proof of concept for a pipeline that spans autoimmune, oncology, respiratory, and other therapeutic areas. For patients, it represents one more option — and potentially a more affordable one — in the ongoing effort to manage diseases that cannot be cured but can, with the right medicine, be controlled.
On September 22, a regulatory committee in Europe took a step that could reshape treatment options for millions of patients living with chronic inflammatory diseases. The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive recommendation for Gobivaz, a biosimilar version of Simponi, the biologic drug golimumab that has become a cornerstone therapy for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
The recommendation came from Alvotech, an Icelandic biotech company founded by Robert Wessman that specializes in developing biosimilar medicines, working in partnership with Advanz Pharma, a London-based pharmaceutical firm focused on specialty and hospital medicines. Alvotech developed the drug and will supply it commercially. Advanz Pharma secured exclusive rights to register and sell it across Europe, the United Kingdom, Switzerland, Canada, Australia, and New Zealand.
Biosimilars are drugs manufactured to closely replicate biologic medicines that have already been approved and are no longer under patent protection. They are not generics in the traditional sense—biologics are far too complex to simply copy. Instead, companies must develop their own versions through sophisticated manufacturing processes, then prove through rigorous clinical testing that their product performs essentially the same way as the original. The stakes are high: a successful biosimilar can dramatically lower costs while maintaining efficacy, potentially opening treatment to patients who might otherwise go without.
Gobivaz comes in two formulations: a 50 milligram dose in a 0.5 milliliter pre-filled syringe and a 100 milligram dose in a milliliter formulation, also pre-filled. Both can be delivered via autoinjector, the kind of device patients can use at home. The committee's recommendation covers treatment across all 27 European Union member states, plus Norway, Iceland, and Liechtenstein—a market of roughly 450 million people.
Alvotech's path to this moment involved two key clinical studies. In November 2023, the company published positive results from a pharmacokinetic study in healthy adult volunteers, comparing how their candidate drug AVT05 behaved in the body compared to the original Simponi. Then in April 2024, they released data from a confirmatory efficacy and safety study in patients with moderate to severe rheumatoid arthritis, showing their biosimilar performed comparably to the reference drug. These studies formed the scientific foundation for the regulatory submission.
Golimumab itself works by inhibiting tumor necrosis factor alpha, or TNF-alpha, a protein implicated in the inflammatory cascade that drives these diseases. By blocking it, the drug reduces joint damage, swelling, and pain. For patients with rheumatoid arthritis alone, which affects roughly 1 percent of the global population, access to effective TNF inhibitors has been transformative—but cost remains a barrier in many regions. A biosimilar version could shift that equation.
The committee's positive opinion is not yet final approval. The European Commission must still issue a formal marketing authorization decision, though such decisions typically follow the committee's recommendation. Once approved, Gobivaz will enter a competitive landscape where other golimumab biosimilars already exist or are in development, but each approval expands the total pool of supply and potentially drives prices downward across the market.
For Alvotech, this represents a significant validation of its business model. The company has eight biosimilar candidates in its pipeline targeting autoimmune disorders, eye disease, osteoporosis, respiratory conditions, and cancer. It has built a network of commercial partners spanning the United States, Europe, Japan, China, and much of the developing world. The Gobivaz approval, pending final European Commission sign-off, demonstrates that the company can navigate the complex regulatory pathway from laboratory to patient. For Advanz Pharma, it marks a step toward its stated ambition of building a leading biosimilars presence in Europe. For patients, it means another option—potentially a more affordable one—for managing diseases that have no cure but can be controlled with the right treatment.
Notable Quotes
The positive CHMP opinion for Gobivaz is an important milestone in expanding patient access and marks a significant step forward in Advanz Pharma's ambition to build a leading biosimilars presence in Europe.— Nick Warwick, Chief Medical Officer, Advanz Pharma
We look forward to working with Advanz Pharma to increase access for patients and healthcare professionals to golimumab, as the reference biologic Simponi is an important treatment option for a number of immune-mediated diseases.— Joseph McClellan, Chief Scientific and Technical Officer, Alvotech
The Hearth Conversation Another angle on the story
Why does a biosimilar matter if the original drug already exists and works?
Cost. Simponi is expensive—tens of thousands of dollars per patient per year. A biosimilar, if approved and manufactured efficiently, can cost significantly less while delivering the same clinical benefit. That price difference determines whether a patient gets treated or goes without.
But how do you prove a biosimilar is actually equivalent? You can't just copy a biologic the way you'd copy a chemical drug.
Exactly. Alvotech had to run clinical studies showing their version behaves the same way in the body and produces the same therapeutic effect. They tested it in healthy volunteers first, then in actual patients with rheumatoid arthritis. The data had to match the original closely enough to satisfy regulators.
What happens now that the committee said yes?
The European Commission makes the final call, but that's usually a formality. Once approved, Gobivaz can be prescribed across the EU and several other countries. It enters a market where other golimumab biosimilars exist, so competition increases and prices tend to fall—good for patients, challenging for manufacturers.
Who benefits most from this approval?
Patients who need TNF inhibitors but can't afford them at current prices. Also healthcare systems in countries with tight budgets. And Alvotech itself—it validates their entire business model and gives them momentum for their other eight biosimilar candidates in development.
Is there any risk to patients from a biosimilar?
Theoretically, no—if the approval process works as intended. The regulatory bar is high. But biosimilars are still newer than the originals, so long-term safety data is still accumulating. That said, the clinical evidence so far has been reassuring.
Why partner with Advanz Pharma instead of selling directly?
Alvotech is a manufacturer and developer. Advanz has the commercial infrastructure already in place—sales teams, relationships with hospitals and doctors, distribution networks across Europe. Partnering lets Alvotech focus on what it does best while Advanz handles the market.